Gland Pharma Limited — Investor Meet, 11-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma Limited reported a revenue of INR 14,058 million for Q2 FY25, reflecting a 2% year-over-year growth. The base business grew 5%, with strong performance in the U.S. core markets. However, Cenexi faced challenges due to an annual shutdown, resulting in a negative EBITDA. The company is optimistic about future growth potential, especially following new product launches and a strategic partnership with Dr. Reddy's. Leadership transition aims to strengthen market presence.